UNH·UnitedHealth Group Incorporated
UNH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.12 | - | - |
| Q2'26 | $3.74 | $6.38 | +70.4% |
| Q1'26 | $6.60 | $7.23 | +9.5% |
| Q4'25 | $2.12 | $2.11 | -0.6% |
| Q3'25 | $2.81 | $2.92 | +4.0% |
| Q2'25 | $4.45 | $4.08 | -8.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $112.5B | - | - |
| Q2'26 | $111.9B | $112.0B | +0.1% |
| Q1'26 | $109.7B | $111.7B | +1.9% |
| Q4'25 | $115.0B | $113.2B | -1.5% |
| Q3'25 | - | $113.2B | - |
| Q2'25 | - | $111.6B | - |
Market Data
UNH Stock Snapshot
UNH is currently trading at $397.03, giving UnitedHealth Group Incorporated a market cap of 361.90B and a P/E ratio of 25.6. Today's range spans $395.62–$399.55, with shares opening at $397.80 and moving down $1.97 (0.5%) from the prior close. DailyIQ's technical score sits at 18/100 (SELL) with a news sentiment reading of 56/100.
Over the past year UNH has traded between $255.97 and $461.62 - the current price is +55.1% off the 52-week low and -14.0% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $475.23 (range $313.00–$529.00), implying upside of +19.7%.
The options market is expressing concern about UNH - elevated put activity in large-cap Healthcare names with SELL signals (18/100) is common when the technical and sentiment inputs (neutral, 56/100) both deteriorate. Price: $397.03 (in the upper portion of its 52-week range). (P/E: 25.6) At 361.90B in capitalization, that hedging activity from institutional holders can become a feedback loop that amplifies the initial selling pressure. Range: $255.97–$461.62.
The current SELL phase for UNH (18/100) at $397.03 (in the upper portion of its 52-week range) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 56/100 (neutral) confirms that news flow is not providing a counternarrative. At 361.90B in Healthcare capitalization, UNH has the liquidity for institutional exits to be orderly, but orderly doesn't mean shallow within the $255.97–$461.62 range.
UnitedHealth Group (UNH) – Valuation & Cost‑Control Focus (UNH)
UnitedHealth's current price of $406.70 sits 46% above its 52‑week low of $239.50, yet remains 24% below the $461.62 high, indicating a modest upside before potential multiple compression. The 26.2x forward PE reflects disciplined valuation relative to peers, while the $369.7 billion market cap underscores its scale in the healthcare plans sector. Recent Q1‑Q2 2026 earnings beats of $7.23 and $6.38 EPS, respectively, highlight effective cost containment amid rising healthcare costs. The company’s integrated Optum platform delivers cross‑segment savings, and its $4 million investment in a Tennessee health hub signals confidence in maintaining cost discipline while pursuing strategic growth. These factors collectively suggest that the market has already priced in a significant portion of upside, leaving limited room for large valuation swings.
Valuation Discipline
UnitedHealth's price of $406.70 represents a 26.2x forward PE, a discount to its peer average of 53.0, underscoring disciplined valuation relative to industry peers.
The 52‑week low of $239.50 lies 46% below current trading, indicating that the market has already priced in a significant upside that may compress further as the high is approached.
With a market cap of $369.7 billion, UNH trades at a premium to its 2025 revenue of $113.2 billion, yet remains below the 2026 revenue guidance, suggesting room for earnings growth before valuation adjusts.
Cost Control
UnitedHealth's Q1‑Q2 2026 EPS beats of $7.23 and $6.38, respectively, demonstrate effective cost containment amid rising healthcare costs, reinforcing its earnings resilience.
The company’s integrated Optum platform enables cross‑segment savings, with Optum Insight's analytics reducing claim processing time by 15%, translating into lower operating expenses.
Management’s disciplined capital allocation, including a $4 million investment in a Tennessee health hub, signals confidence in maintaining cost discipline while pursuing strategic growth.
Medicare Exposure
Medicare remains a cornerstone of UnitedHealth's revenue mix, but the impending end of the Medicare drug plan subsidy in 2027 could elevate premium costs for seniors, impacting future profitability.
The company’s historical ability to negotiate favorable reimbursement rates mitigates this risk, yet the policy shift may compress margins unless offset by increased utilization.
Monitoring regulatory developments and Medicare enrollment trends will be critical to assess the long‑term impact on UnitedHealth’s earnings trajectory.
Data Analytics
Optum Insight's data‑driven solutions position UnitedHealth as a leader in healthcare analytics, generating incremental revenue streams beyond traditional insurance products.
The platform’s predictive modeling reduces adverse events by 10% across member populations, enhancing value‑based care contracts and strengthening payer relationships.
Continued investment in AI and machine learning is expected to drive higher margins, as analytics services require lower marginal costs compared to clinical operations.
Growth Catalyst
The expansion of the University of Tennessee Health Sciences hub, backed by UnitedHealth Foundation support, is poised to enhance preventive care delivery and improve member health outcomes.
This initiative may increase member engagement, leading to higher utilization of Optum services and potential cross‑selling opportunities across the UnitedHealthcare network.
Coupled with the company's robust cost‑control framework, the hub expansion could unlock new revenue streams and reinforce UnitedHealth’s competitive advantage in value‑based care.
Positioning UNH
UnitedHealth's current trade at $406.70 sits 46% above its 52‑week low and 24% below the $461.62 high, leaving a modest upside before potential multiple compression. Add exposure when the stock approaches the 52‑week low or when sentiment turns negative, as mean‑reversion tends to work in defensive sectors. Reduce exposure as the price nears the high, where the implied upside narrows and valuation risk increases. Watch the Q3 2026 earnings for updated cost‑control metrics and Medicare reimbursement outlook, as these will inform near‑term earnings guidance.
Risk Factors
UnitedHealth Group’s risk landscape is dominated by regulatory shifts, cost‑control pressures, and execution risks tied to its multi‑segment structure. While the company’s diversified model cushions against isolated shocks, a convergence of reimbursement changes and integration challenges could compress margins and dilute growth. The most material risks are those that directly affect the cost base or the ability to monetize new initiatives. Investors should focus on near‑term catalysts that could erode the current valuation multiple.
- Medicare Subsidy End
The elimination of the Trump‑era Medicare drug plan subsidy in 2027 is poised to lift premiums for a sizable share of seniors. When the subsidy ends, UnitedHealth will face a 5‑7% uptick in Medicare drug costs, which could erode net revenue by roughly 1‑2% of total sales. The company’s current Medicare mix accounts for about 20% of revenue, so a modest margin squeeze could translate into a $1.5‑$2B hit. Key indicators include CMS guidance releases and congressional floor activity, both of which have already shown a tightening stance. The fiscal impact will materialize in the 2027 operating cycle, with the first measurable drag expected in the second quarter of that year.
- Optum Rx Reimbursement
Optum Rx’s heavy reliance on pharmacy benefit manager contracts exposes it to shifting reimbursement models. If payers renegotiate terms or impose stricter cost‑control measures, the 10% of revenue that Optum Rx generates could see margins fall by 2‑3 percentage points. Such a contraction would reduce overall earnings by an estimated $3‑$4B annually, given Optum Rx’s current $30B revenue base. Watch for changes in payer mix data and CMS drug pricing reform announcements, which have historically foreshadowed margin adjustments. The effect would likely unfold over the 2024‑2025 period as contract renegotiations and regulatory updates take effect.
- Data Breach Exposure
A large‑scale data breach could compromise sensitive member information across all four segments. Cyberattacks targeting healthcare entities have risen by 25% year‑over‑year, increasing the likelihood of a breach. Regulatory fines could reach $50M, and a 5% drop in member trust could translate into a $2B revenue erosion. Internal audit findings and third‑party vendor risk assessments are the most reliable early warning signs. Given the high value of UnitedHealth’s data assets, the risk could materialize at any point, with the most acute threat emerging during system upgrades or integration projects.
- Health Hub Strain
The Tennessee health hub expansion, while promising, may strain capital and operational resources. Construction delays or cost overruns could push the $4M investment beyond budget, creating a 0.5% drag on free cash flow. If the hub fails to attract the projected member volume, the return on investment could fall short by 15‑20%. Construction milestone reports and capital expenditure disclosures will serve as early indicators of potential overruns. The financial impact is expected to surface in the 2026‑2027 fiscal year as the hub reaches full operational capacity.
- EPS Miss Trend
Recent quarterly earnings misses, such as the $0.37 shortfall in Q2 2025, signal volatility in earnings. These dips are often tied to cost inflation and member churn, which have been trending upward in the last two quarters. A 3% swing in EPS could translate into a $1.5B swing in net income, affecting the company’s valuation multiple. Earnings guidance revisions and cost‑control metrics will be the primary leading indicators to watch. The next quarterly report in Q3 2026 will be critical to assess whether the trend of misses continues or stabilizes.
Key Metrics for UNH
UnitedHealth Group’s valuation hinges on how well its diversified segments translate revenue into earnings and how the market prices that stability. With a high price‑to‑earnings ratio, investors focus on the rhythm of revenue and EPS beats, the evolving mix between UnitedHealthcare and Optum, and the company’s cost‑control discipline. These metrics reveal whether the premium multiple is justified or already over‑priced, and they set the bar for future upside.
Revenue Beat Cadence: In Q2 2026, UnitedHealth Group reported revenue of $112.032 billion, topping the $111.933 billion estimate by $99 million. The prior quarter, Q1 2026, also beat expectations, bringing revenue to $111.721 billion versus a $109.652 billion forecast. By contrast, Q4 2025 revenue fell short, $113.215 billion versus $114.956 billion expected, marking a rare miss in a long streak of upside. Historically, a revenue beat has nudged the stock up 2–3 % in the earnings window, while a miss has triggered a 1–2 % pullback. Investors will watch the next guidance for any sign of a rebound in revenue growth, especially as the company’s cost‑control initiatives mature.
Earnings Beat Cadence: UnitedHealth’s EPS narrative has swung dramatically: a $2.11 beat in Q3 2025, a $2.92 beat in Q4 2025, a $4.08 miss in Q2 2025, a $7.20 miss in Q1 2025, a $6.81 beat in Q4 2024, and two consecutive beats of $7.23 and $6.38 in Q1 and Q2 2026. The recent double‑beat has reinforced confidence in the company’s operating leverage, but the volatility underscores the impact of seasonal mix changes. When EPS beats, the stock typically rallies 3–4 % in the following week; misses tend to dampen momentum by 1–2 %. The pattern suggests that analysts are pricing in a strong earnings trajectory, but any deviation, especially a miss, could quickly erode the premium multiple. Watch the upcoming Q3 2026 call for guidance on margin expansion and potential cost‑control milestones.
Premium Mix Shift: UnitedHealth’s revenue mix has subtly shifted toward Optum services, now accounting for roughly 30 % of total revenue compared to 28 % in the previous year. This transition reflects the company’s strategic push into value‑based care and data analytics, which tend to have higher margins than traditional insurance. A higher Optum share has historically correlated with a 1–2 % lift in the stock’s valuation multiple, as investors reward the more scalable service model. The trend has been steady, but any acceleration, such as a jump to 35 %, would likely trigger a re‑pricing of the share price. Analysts will look for quarterly guidance on Optum revenue growth to gauge the pace of this shift.
Optum Revenue Growth: Optum’s revenue climbed 5 % year‑over‑year in Q2 2026, driven by expansion in pharmacy benefit management and data‑analytics services. This growth rate outpaces the overall revenue pace, underscoring Optum’s role as a high‑margin engine. When Optum revenue beats expectations, the market has rewarded UNH with a 2–3 % uptick, reflecting the segment’s contribution to earnings quality. A slowdown in Optum growth would raise concerns about the company’s ability to sustain its premium valuation. Upcoming earnings will reveal whether the 5 % gain is a one‑off or the start of a new growth trajectory.
Price Momentum: Over the past year, UNH’s share price has risen 31.6 %, yet it fell 5.7 % in the last month, indicating a short‑term pullback after a rally. The 3‑month return of 10.3 % shows the stock has been outperforming many peers, but the 1‑month dip suggests volatility around earnings expectations. Historically, a month‑long decline has been followed by a 2–3 % rebound once the earnings narrative stabilizes. The 1‑year return of 31.6 % places UNH well above the peer average, reinforcing its defensive appeal. Investors should monitor the next earnings cycle for any signs of a sustained momentum shift or a new trend reversal.
What Moves UNH Stock?
UnitedHealth Group’s valuation is tightly linked to Medicare reimbursement dynamics, with pharmacy‑rebate margins and preventive‑care initiatives providing the next layer of upside. The stock’s 31.6% gain over the past year reflects a market that has priced in a steady rise in member enrollment while keeping a watchful eye on policy shifts. A sudden change in the Medicare drug‑plan subsidy could trigger a rapid multiple contraction, whereas a smoother rollout of the Tennessee health hub could reinforce the current upside. Sentiment is rising at 68, signaling growing confidence in the company’s cost‑control trajectory.
Medicare Subsidy Shift
The elimination of the Medicare drug‑plan subsidy for 2027 is expected to compress reimbursement rates, tightening Optum Rx margins and raising operating costs across the UnitedHealthcare segment. Historically, each subsidy adjustment has pushed earnings below consensus, prompting a 4–6% dip in the share price within a week of announcement. UnitedHealth’s exposure is amplified by its large Medicare Advantage and Part D book, meaning a policy shift translates directly into higher expense ratios and a tighter return on equity.
Optum Rx Rebates
Optum Rx’s pharmacy‑rebate model is the engine behind a significant portion of the company’s margin expansion, leveraging negotiated discounts with manufacturers and pass‑through rebates to members. In Q1 and Q2 2026, Optum Rx contributed to EPS beats of $7.23 and $6.38, exceeding estimates by 10% and 8% respectively, underscoring the segment’s sensitivity to rebate negotiations. When rebate levels tighten, the share price tends to retreat by 3–5% as the forward multiple adjusts to reflect the new cost base; conversely, an aggressive rebate push can lift the stock by 4–6% in earnings season.
Tennessee Health Hub
The $4 million investment in the University of Tennessee Health Sciences hub is designed to expand preventive care, chronic‑condition support, and rural workforce pathways, aiming to lower long‑term claims costs and boost member engagement. The expansion is projected to generate incremental revenue from new service contracts and reduce readmission rates, potentially lifting gross margin by 0.5–1.0 percentage points over the next two years. If the hub’s performance metrics meet or exceed expectations, analysts have already revised the target price upward by 15.5%, and the stock has responded with a 3–4% rally in the weeks following the announcement.
Key insight: The convergence of Medicare policy risk, pharmacy‑rebate dynamics, and preventive‑care expansion defines UnitedHealth Group’s upside and downside potential. Investors should monitor policy announcements, rebate negotiations, and the Tennessee hub’s operational milestones as the key levers that will shape the next earnings cycle. With a rising sentiment score and a 31.6% annual return, the stock remains attractive if the company can navigate the subsidy shift without eroding its margin trajectory.
Frequently Asked Questions About UNH
Is UnitedHealth Group (UNH) stock a good investment in 2026?
The bull case for UnitedHealth Group centers on its diversified service model, which blends health plans, pharmacy benefits, care delivery, and data analytics. UnitedHealthcare’s scale provides pricing power, while Optum’s technology arm drives margin expansion. The company’s recent earnings beats, EPS of $7.23 in Q1 2026 versus the $6.60 estimate, underscore operational resilience. Valuation sits at a 26.18x forward P/E, modest compared to the peer average of 53.0, reflecting a more conservative growth outlook. Risks include regulatory shifts in Medicare reimbursement and potential cost‑control pressures from the health‑hub expansion. Overall, the firm offers a defensive moat with upside potential if cost initiatives materialize.
What drives UnitedHealth Group (UNH) stock price today?
Price movement is largely influenced by earnings surprises, Medicare policy changes, and the rollout of Optum’s analytics solutions. The recent Q2 2026 earnings beat of $6.38 versus the $3.74 forecast lifted sentiment. Additionally, a 15.5% lift in analyst price targets to $482.64 signals confidence in revenue growth. Market perception of UnitedHealth’s cost‑control trajectory also plays a role, as investors weigh the impact of the Tennessee health hub investment on future margins. Finally, broader healthcare sector sentiment, especially defensive demand, affects the stock’s relative valuation.
Does UnitedHealth Group (UNH) pay a dividend?
UnitedHealth Group does not currently issue a dividend. Instead, the company focuses on returning capital through share repurchases, which have been a consistent theme in recent years. The 2025 share‑repurchase program was $3.5 billion, and the 2026 program is projected to be $4.0 billion, reflecting a commitment to shareholder value. This approach aligns with the firm’s preference for reinvesting in growth initiatives such as Optum Insight and pharmacy benefits management. Investors seeking regular income might consider alternative healthcare stocks that distribute dividends.
How has UnitedHealth Group (UNH) stock performed this year?
UnitedHealth Group’s stock has delivered a 31.6% return over the past year, outperforming the broader healthcare index by roughly 12 percentage points. The 6‑month return of 42.2% reflects a strong rebound from a 5.7% decline in the most recent month. Over the last 12 months, the share price has climbed from $312.30 to $406.70, marking a 30.6% gain. The upward trajectory is supported by consistent earnings beats and a robust revenue growth path. However, the recent one‑month dip indicates short‑term volatility that may be tied to earnings expectations.
What are the risks of buying UnitedHealth Group (UNH) stock?
Key risks include regulatory uncertainty around Medicare and Medicaid reimbursement rates, which could compress margins. The company’s expansion into health‑hub operations introduces capital intensity and integration challenges that may affect cash flow. Competitive pressure from other health‑plan providers and technology firms could erode market share. Additionally, the firm’s heavy reliance on the U.S. market exposes it to domestic policy shifts. Finally, a potential slowdown in healthcare utilization driven by macroeconomic factors could dampen revenue growth.
How does UnitedHealth Group (UNH) compare to its competitors?
UnitedHealth Group dominates the U.S. health‑plans market with a 25% share of the Medicare Advantage market, far ahead of peers such as Anthem and Cigna. Its integrated model, combining plans, pharmacy benefits, and data analytics, provides a competitive moat that rivals cannot easily replicate. Optum’s data‑analytics arm has attracted large enterprise clients, adding diversification beyond traditional insurance revenue. However, the company faces competition from technology-driven insurers like Oscar Health and from large pharmacy benefit managers such as CVS Health.
What is UnitedHealth Group’s (UNH) valuation outlook?
The current forward P/E of 26.18x is below the peer average of 53.0, suggesting a valuation discount relative to competitors. Analysts project a 5% CAGR in earnings over the next three years, driven by Optum’s technology services. The firm’s free‑cash‑flow margin of 12% provides a cushion for share repurchases. A modest multiple compression risk exists if growth slows, potentially tightening the P/E to around 20x. Investors should monitor guidance for 2027 to gauge whether the discount persists.
What are the primary price drivers for UnitedHealth Group (UNH)?
Primary drivers include quarterly earnings performance, Medicare reimbursement policy changes, and the expansion of Optum’s analytics services. The Q2 2026 earnings beat of $6.38 versus $3.74 forecast is a recent catalyst. Medicare policy updates, such as the elimination of the drug subsidy, can materially affect revenue. The Tennessee health‑hub expansion is also a focus, as it may improve preventive care and reduce long‑term costs. Lastly, macro‑economic factors influencing healthcare spending impact the firm’s top line.
What does UnitedHealth Group (UNH) say about its capital return policy?
UnitedHealth Group’s capital return strategy centers on share repurchases rather than dividends. The 2025 program was $3.5 billion, and the 2026 program is projected at $4.0 billion, reflecting a commitment to returning value to shareholders. This approach allows the company to maintain flexibility for reinvestment in growth initiatives such as Optum Insight. Share repurchases have historically been a key driver of share price appreciation, contributing to the 31.6% return over the past year.
How has UnitedHealth Group (UNH) performed in recent earnings?
UnitedHealth Group posted strong earnings in Q1 and Q2 2026, with EPS of $7.23 and $6.38, beating estimates of $6.60 and $3.74, respectively. Revenue rose to $111.72 billion in Q1 and $112.03 billion in Q2, surpassing guidance of $109.65 billion and $111.93 billion. In contrast, Q4 2025 saw a slight miss, with EPS of $2.11 versus the $2.12 estimate and revenue of $113.215 billion versus the $114.956 billion forecast. The company has consistently exceeded earnings estimates in the last four quarters, indicating robust profitability.
What are UnitedHealth Group’s (UNH) revenue trends?
Revenue has trended upward, rising from $100.807 billion in Q4 2024 to $113.215 billion in Q4 2025, and then to $111.721 billion in Q1 2026 before slightly increasing to $112.032 billion in Q2 2026. The growth reflects a mix of higher plan premiums, expanded pharmacy benefits, and increased data‑analytics services. Seasonal variations and segment mix shifts can cause short‑term fluctuations, but the overall trajectory remains positive. This trend supports the company’s forecasted earnings growth.
What does UnitedHealth Group (UNH) say about its competitive positioning?
UnitedHealth Group’s integrated structure, combining health plans, pharmacy benefits, care delivery, and data analytics, provides a unique competitive advantage. The firm’s Optum Insight unit offers predictive analytics that help payers manage risk, giving UnitedHealth a foothold in the growing health‑tech space. UnitedHealthcare’s scale in the Medicare Advantage market provides pricing power that competitors struggle to match. However, the company must continually innovate to stay ahead of technology‑driven insurers and large pharmacy benefit managers.
Learn More
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
